PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma

Oncogene

Volumn 31, Issue 10, 2012, Pages 1264-1274

  Molina, J R ^a   Agarwal, N K ^a   Morales, F C ^a   Hayashi, Y ^a   Aldape, K D ^a   Cote, G ^a   Georgescu, M M ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Akt; glioblastoma; NHERF1; PHLPP; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLECKSTRIN HOMOLOGY DOMAIN LEUCINE RICH REPEAT PROTEIN PHOSPHATASE 1; PROTEIN KINASE B; SODIUM PROTON EXCHANGER REGULATORY FACTOR 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

AGED; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SODIUM-HYDROGEN ANTIPORTER; TUMOR SUPPRESSOR PROTEINS;

EID: 84858003974     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.324     Document Type: Article

References (40)

1. Alessi DR, Kozlowski MT, Weng QP, Morrice N, Avruch J. (1998). 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 8: 69-81. (Pubitemid 28104519)
2. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C et al. (2007). NCBI GEO: mining tens of millions of expression profiles-database and tools update. Nucleic Acids Res 35: D760-D765. (Pubitemid 46056306)
3. Brognard J, Newton AC. (2008). PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab 19: 223-230. (Pubitemid 351993013)
4. Brognard J, Sierecki E, Gao T, Newton AC. (2007). PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25: 917-931. (Pubitemid 46436532)
5. Cardone RA, Bellizzi A, Busco G, Weinman EJ, Dell'Aquila ME, Casavola V et al. (2007). The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 18: 1768-1780. (Pubitemid 46717558)
6. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. (2008). The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8: 187-198. (Pubitemid 351688437)
7. Courtney KD, Corcoran RB, Engelman JA. (2010). The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083.
8. Fouassier L, Yun CC, Fitz JG, Doctor RB. (2000). Evidence for ezrinradixin- moesin-binding phosphoprotein 50 (EBP50) self-association through PDZ-PDZ interactions. J Biol Chem 275: 25039-25045. (Pubitemid 30626614)
9. Franke TF. (2008). PI3K/Akt: getting it right matters. Oncogene 27: 6473-6488.
10. Gao T, Furnari F, Newton AC. (2005). PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18: 13-24. (Pubitemid 40444644)
11. Georgescu MM. (2010). PTEN tumor suppressor network in PI3KAkt pathway control. Genes & Cancer 1: 1170-1177.
12. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. (1999). The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA 96: 10182-10187. (Pubitemid 29422533)
13. Georgescu MM, Morales FC, Molina JR, Hayashi Y. (2008). Roles of NHERF1/EBP50 in cancer. Curr Mol Med 8: 459-468.
14. Hall RA, Ostedgaard LS, Premont RT, Blitzer JT, Rahman N, Welsh MJ et al. (1998). A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc Natl Acad Sci USA 95: 8496-8501.
15. Hayashi Y, Molina JR, Hamilton SR, Georgescu MM. (2010). NHERF1/EBP50 is a new marker in colorectal cancer. Neoplasia 12: 1013-1022.
16. Kreimann EL, Morales FC, de Orbeta-Cruz J, Takahashi Y, Adams H, Liu TJ et al. (2007). Cortical stabilization of betacatenin contributes to NHERF1/EBP50 tumor suppressor function. Oncogene 26: 5290-5299. (Pubitemid 47237631)
17. Lazar CS, Cresson CM, Lauffenburger DA, Gill GN. (2004). The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. Mol Biol Cell 15: 5470-5480. (Pubitemid 39564739)
18. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y et al. (1999). Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99: 323-334. (Pubitemid 29519911)
19. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947. (Pubitemid 27148818)
20. Liu J, Weiss HL, Rychahou P, Jackson LN, Evers BM, Gao T. (2009). Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene 28: 994-1004.
21. Maehama T, Dixon JE. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378. (Pubitemid 28268370)
22. Maudsley S, Zamah AM, Rahman N, Blitzer JT, Luttrell LM, Lefkowitz RJ et al. (2000). Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity. Mol Cell Biol 20: 8352-8363.
23. Molina JR, Hayashi Y, Stephens C, Georgescu MM. (2010a). Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia 12: 453-463.
24. Molina JR, Morales FC, Hayashi Y, Aldape KD, Georgescu MM. (2010b). Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. Cancer Res 70: 6697-6703.
25. Morales FC, Takahashi Y, Momin S, Adams H, Chen X, Georgescu MM. (2007). NHERF1/EBP50 head-to-tail intramolecular interaction masks association with PDZ domain ligands. Mol Cell Biol 27: 2527-2537. (Pubitemid 46581344)
26. Murthy A, Gonzalez-Agosti C, Cordero E, Pinney D, Candia C, Solomon F et al. (1998). NHE-RF, a regulatory cofactor for Na(+)-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins. J Biol Chem 273: 1273-1276. (Pubitemid 28133639)
27. Pan Y, Weinman EJ, Dai J. (2008). NHERF1 (Na+/H+ exchanger regulatory factor 1) inhibits platelet-derived growth factor signaling in breast cancer cells. Breast Cancer Res 10: R5.
28. Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W et al. (2010). Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 38: 512-523.
29. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. (2009). A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci USA 106: 480-485.
30. Reczek D, Berryman M, Bretscher A. (1997). Identification of EBP50: a PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family. J Cell Biol 139: 169-179. (Pubitemid 27444089)
31. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. (Pubitemid 40262113)
32. Shenolikar S, Minkoff CM, Steplock DA, Evangelista C, Liu M, Weinman EJ. (2001). N-terminal PDZ domain is required for NHERF dimerization. FEBS Let 489: 233-236. (Pubitemid 32126415)
33. Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S. (2003). EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology 38: 178-186. (Pubitemid 36775809)
34. Shimizu K, Okada M, Takano A, Nagai K. (1999). SCOP, a novel gene product expressed in a circadian manner in rat suprachiasmatic nucleus. FEBS Lett 458: 363-369. (Pubitemid 29433836)
35. Song J, Bai J, Yang W, Gabrielson EW, Chan DW, Zhang Z. (2007). Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer. Histopathology 51: 40-53. (Pubitemid 46976376)
36. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362. (Pubitemid 27147102)
37. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S et al. (2006). Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9: 287-300.
38. Takahashi Y, Morales FC, Kreimann EL, Georgescu MM. (2006). PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J 25: 910-920. (Pubitemid 43292451)
39. Walker SM, Leslie NR, Perera NM, Batty IH, Downes CP. (2004). The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J 379: 301-307. (Pubitemid 38570102)
40. Weinman EJ, Steplock D, Tate K, Hall RA, Spurney RF, Shenolikar S. (1998). Structure-function of recombinant Na/H exchanger regulatory factor (NHE-RF). J Clin Invest 101: 2199-2206. (Pubitemid 28244103)